Therapeutic equivalence requires pharmaceutical, pharmacokinetic, and pharmacodynamic identities: True bioequivalence of a generic product of intravenous metronidazole

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 5, 2012, Pages 2659-2665

  Agudelo, M ^a   Vesga, O ^a  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; METRONIDAZOLE;

ANAEROBIC INFECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTEROIDES FRAGILIS; BIOEQUIVALENCE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; ESCHERICHIA COLI; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; STEADY STATE;

ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BACTEROIDES FRAGILIS; BACTEROIDES INFECTIONS; CHROMATOGRAPHY, LIQUID; DRUGS, GENERIC; FEMALE; INJECTIONS, INTRAVENOUS; MASS SPECTROMETRY; METRONIDAZOLE; MICE; MICROBIAL SENSITIVITY TESTS; NEUTROPENIA; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; THERAPEUTIC EQUIVALENCY; THIGH;

EID: 84860196607     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06012-11     Document Type: Article

References (21)

1. Agudelo M, Pelaez C, Kulawy R, Vesga O. 2011. Bioanalytical comparison of generic products of imipenem-cilastatin and meropenem with their respective innovators and reference compounds, abstr A2-561. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL.
2. Agudelo M, Perez JA, Pelaez C, Vesga O. 2011. Differences in susceptibility to hydrolysis by murine dehydropeptidase-I (DHP-I) of generic carbapenems compared with their respective innovators in vitro, abstr A2-562. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL.
3. Bennett JV, Brodie JL, Benner EJ, Kirby WMM. 1966. Simplified, accurate method for antimicrobial assay of clinical specimens. Appl. Microbiol. 14:170 -177.
4. Clinical and Laboratory Standards Institute. 2009. Performance standards for antimicrobial susceptibility testing, approved standard M100- S19. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Chua K, Howden BP. 2010. Metronidazole, p 1211-1237. In Grayson ML (ed), Kucer's the use of antibiotics, 6th ed. Hodder Arnold Ltd, London, United Kingdom.
6. Craig WA. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-10.
7. Drusano GL. 2004. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat. Rev. Microbiol. 2:289 -300.
8. Dure P, Couture J, Collart P, Girot C. 1960. Flagyl (metronidazole). Br. J. Vener. Dis. 36:154 -162.
9. Glantz SA, Slinker BK. 2001. Primer of applied regression and analysis of variance, 2nd ed. McGraw-Hill Companies, Inc, New York, NY.
10. Glantz SA. 2002. How to test for trends, p 230-297. In Glantz SA (ed), Primer of biostatistics, 5th ed. McGraw-Hill Companies, Inc, New York, NY.
11. Lewis RE, Klepser ME, Ernst EJ, Snabes MA, Jones RN. 2000. Comparison of oral immediate-release (IR) and extended-release (ER) metronidazole bactericidal activity against Bacteroides spp. using an in vitro model of infection. Diagn. Microbiol. Infect. Dis. 37:51-55. (Pubitemid 30224524)
12. Mastoraki E, et al. 2008. Incidence of postoperative infections in patients undergoing coronary artery bypass grafting surgery receiving antimicrobial prophylaxis with original and generic cefuroxime. J. Infect. 56:35-39. (Pubitemid 350253651)
13. Ralph ED, Claske JT, Libke RD, Luthy RP, Kirby WMM. 1974. Pharmacokinetics of metronidazole as determined by bioassay. Antimicrob. Agents Chemother. 6:691- 696.
14. Rodríguez CA, Agudelo M, Zuluaga AF, Vesga O. 2010. In vitro and in vivo comparison of the anti-staphylococcal efficacy of generic products and the innovator of oxacillin. BMC Infect. Dis. 10:153.
15. Rodríguez CA, Agudelo M, Cataño JC, Zuluaga AF, Vesga O. 2009. Potential therapeutic failure of generic vancomycin in a liver transplant patient with MRSA peritonitis and bacteremia. J. Infect. 59:277-280.
16. Rodriguez CA, Agudelo M, Zuluaga AF, Vesga O. 2012. Generic vancomycin enriches resistant subpopulations of Staphylococcus aureus after exposure in a neutropenic mouse thigh infection model. Antimicrob. Agents Chemother. 56:243-247.
17. Taylor RB, et al. 2001. Pharmacopoeial quality of drugs supplied by Nigerian pharmacies. Lancet 357:1933-1936. (Pubitemid 32568335)
18. Vesga O, Agudelo M, Salazar BE, Rodriguez CA, Zuluaga AF. 2010. Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator. Antimicrob. Agents Chemother. 54:3271-3279.
19. Zuluaga AF, et al. 2006. Neutropenia induced in outbred mice by a simplified low-dose cyclophosphamide regimen: characterization and applicability to diverse experimental models of infectious diseases. BMC Infect. Dis. 6:55.
20. Zuluaga AF, Agudelo M, Rodriguez CA, Vesga O. 2009. Application of microbiological assay to determine pharmaceutical equivalence of generic intravenous antibiotics. BMC Clin. Pharmacol. 9:1.
21. Zuluaga AF, Agudelo M, Cardeño JJ, Rodriguez CA, Vesga O. 2010. Determination of therapeutic equivalence of generic products of gentamicin in the neutropenic mouse thigh infection model. PLoS One 5:e10744.